Clinical Development Team

The Clinical Development Team at Kynexis is responsible for designing and overseeing clinical trials to evaluate the safety and efficacy of KYN-5356, the company’s lead candidate for treating cognitive impairment associated with schizophrenia. This multidisciplinary team collaborates on regulatory submissions, manages the logistics of clinical trial operations, and integrates translational science insights to optimize patient stratification using biomarker data. Their goal is to ensure that Kynexis advances its innovative therapeutic approach while adhering to regulatory standards and industry best practices.